BSECAPRIHANS INDIA LTD.· Industrial ProductsHighNeutral
Announced Mon, 10 Aug, 2026 · 21:43 IST

Q1 FY27 results: revenue up 22 percent YoY, profit rebounds; Director exits

Revenue Growth 20pctPat Growth 25pctEmphasis Of MatterRelated Party TransactionsResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+17.5%Reaction day
₹79.00
prior close
₹86.90
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.2%+17.7% vs market
Plastic Products - Industrial peers, median of 39sector+0.0%+17.5% vs sector

On the reaction day the stock moved 17.7 pts more than Nifty Microcap 250 and 17.5 pts more than its Plastic Products - Industrial peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+6.8
10m
+6.8
15m
+6.8
30m
+6.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+17.5-0.2+17.7+0.0+17.5
Next day
+29.1+0.2+28.9+0.0+29.1
2d
+26.6+0.4+26.2+0.4+26.2
3d
+32.3+0.4+31.9+1.2+31.1
4d
+45.6+0.6+45.0+0.0+45.6
5d
+60.1+0.9+59.1-0.2+60.2
1w
+72.2+0.9+71.3+1.0+71.2
15d
+38.0+0.9+37.0+2.2+35.8
1m
+50.4+2.3+48.0-1.1+51.5
2m
+27.7-1.1+28.8-2.0+29.7
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Plastic Products - Industrial peers, median of 39Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Caprihans India posted Q1 FY27 standalone revenue of Rs 220.16 Cr versus Rs 181.81 Cr in Q4 FY26. Consolidated revenue rose about 22 percent YoY to Rs 221.39 Cr from Rs 181.89 Cr. Standalone PAT was Rs 7.01 Cr vs Rs 6.31 Cr. Consolidated PAT swung to Rs 6.22 Cr profit from Rs 13.56 Cr loss a year ago. Independent Director Avinash Joshi resigned for personal reasons and stepped down as Audit Committee Chair. Audit Committee reconstituted from August 11. Auditor issued unqualified review noting the Bilcare PFD arrangement.

Likely market impact

Strong rebound in revenue and profit lifts sentiment. Director exit and committee reshuffle need monitoring.